Skip to content
Members of the Shokeen Molecular Imaging Lab published their recent study in Molecular Imaging Biology demonstrating how cluster of differentiation 38 (CD38) could be a promising therapeutic target in multiple myeloma patients.
The investigators used near-infrared fluorescence imaging to monitor spatiotemporal CD38 expression in preclinical multiple myeloma with the anti-CD38 daratumumab (DARA) conjugated to the NIR fluorophore IRDye800CW (DARA-IRDye800). They found that DARA-IRDye800 could be a promising contrast agent for preclinical evaluation of CD38 expression, opening up the possibility of further investigations of myeloma engraftment and kinetics in relation to anti-CD38 therapies.
Read more in Molecular Imaging Biology.
Opens in a new window
Opens an external site
Opens an external site in a new window